Baicalin Alleviates Thrombin-Induced Inflammation in Vascular Smooth Muscle Cells.

Publisher: Wiley Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: New York, NY : Hindawi Pub. Co.

Atherosclerosis*/drug therapy ; Atherosclerosis*/metabolism ; Muscle, Smooth, Vascular*/metabolism; Inflammation/chemically induced ; Inflammation/drug therapy ; Inflammation/metabolism ; Myocytes, Smooth Muscle/metabolism ; Thrombin/pharmacology ; Flavonoids ; Humans

Atherosclerosis (AS) is a chronic inflammatory disease of the arterial intima. As AS represents the most common type of vascular disease, it affects millions of individuals and is a source of high morbidity and mortality rates worldwide. Overwhelming evidence indicates that AS-related inflammation is mediated by proinflammatory cytokines, chemokines, adhesion molecules and inflammatory signaling pathways, with each of these factors being shown to play critical roles during the entire progression of AS. While a number of drugs have been approved for use in the treatment of AS, their benefits are modest, which underscores the urgency for the development of new drug therapies. In part, these deficits in effective drugs can be attributable to the lack of a clear understanding of the molecular mechanisms of AS. In this study, we investigate the capacity for thrombin to trigger inflammation and induce cell proliferation in vascular smooth muscle cells (VSMCs). We then assessed the effects of baicalin and its potential mechanisms on VSMC inflammation as induced by thrombin. Baicalin, which is a natural bioactive compound of S. baicalensis Georgi (SBG), exerted a protective effect against thrombin-induced VSMC inflammation as resulting from the upregulation of PAR-1. This protection as exerted by baicalin appears to reside in its capacity to produce an inhibitory effect on the thrombin-induced activation of the ERK1/2 pathway. These findings suggest that baicalin may be a promising candidate for the treatment of atherosclerosis.
(Copyright © 2022 Xiaolei Zheng et al.)

The author reports no conflicts of interest in this work.

Int Immunopharmacol. 2021 Jan;90:107170. (PMID: 33218940)
Pharmacol Rep. 2020 Feb;72(1):13-23. (PMID: 32016847)
J Thromb Thrombolysis. 2014 Jan;37(1):45-55. (PMID: 24241912)
Thromb Haemost. 2011 Dec;106(6):1020-33. (PMID: 21979864)
Ann N Y Acad Sci. 1997 Apr 15;811:429-36. (PMID: 9186620)
Front Pharmacol. 2020 Nov 02;11:583200. (PMID: 33224035)
Postepy Hig Med Dosw (Online). 2014 Jan 16;68:10-22. (PMID: 24491891)
Cathet Cardiovasc Diagn. 1990 Jul;20(3):218. (PMID: 2364424)
Aging Dis. 2017 Dec 1;8(6):850-867. (PMID: 29344420)
Annu Rev Immunol. 2002;20:55-72. (PMID: 11861597)
Food Funct. 2019 Jul 17;10(7):4001-4009. (PMID: 31210194)
Thromb Haemost. 2008 Feb;99(2):305-15. (PMID: 18278179)
Vascul Pharmacol. 2014 Aug;62(2):72-81. (PMID: 24924409)
Curr Opin Lipidol. 2012 Dec;23(6):548-53. (PMID: 23069985)
Cardiovasc Res. 2009 Jun 1;82(3):392-403. (PMID: 19228706)
Biomed Pharmacother. 2018 Jul;103:851-857. (PMID: 29710501)
Acta Physiol (Oxf). 2015 May;214(1):33-50. (PMID: 25677529)
Eur J Med Chem. 2017 May 5;131:68-80. (PMID: 28288320)
BioDrugs. 2012 Aug 1;26(4):217-33. (PMID: 22571369)
Pharmacol Res. 2021 Feb;164:105387. (PMID: 33352232)
Clin Sci (Lond). 2021 Feb 12;135(3):447-463. (PMID: 33458764)
Mol Med Rep. 2018 Jan;17(1):1453-1460. (PMID: 29257234)
Trends Mol Med. 2003 Dec;9(12):549-57. (PMID: 14659470)
J Cell Biochem. 2019 Apr;120(4):4757-4765. (PMID: 30269382)
Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):322-328. (PMID: 28165553)
Brain Res Bull. 2020 Nov;164:314-324. (PMID: 32858128)
Int Immunopharmacol. 2014 Nov;23(1):294-303. (PMID: 25239813)
Cardiovasc Ther. 2011 Dec;29(6):349-61. (PMID: 20528879)
Biomed Res Int. 2019 Aug 6;2019:2187306. (PMID: 31467874)
Science. 2002 Dec 6;298(5600):1911-2. (PMID: 12471242)
Pharm Biol. 2018 Dec;56(1):465-484. (PMID: 31070530)
Circ Res. 2016 Feb 19;118(4):692-702. (PMID: 26892967)
J Glaucoma. 2016 Aug;25(8):692-7. (PMID: 26950581)
FASEB J. 2019 Nov;33(11):11776-11790. (PMID: 31365278)
Mol Cell Biochem. 2014 Nov;396(1-2):147-60. (PMID: 25047892)
Xenobiotica. 2010 May;40(5):357-67. (PMID: 20230189)
J Clin Invest. 2001 Feb;107(3):255-64. (PMID: 11160146)
Nat Rev Dis Primers. 2019 Aug 16;5(1):56. (PMID: 31420554)
Acta Med Indones. 2007 Apr-Jun;39(2):86-93. (PMID: 17933075)
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):13-24. (PMID: 30580574)
Nat Rev Cardiol. 2019 Jul;16(7):389-406. (PMID: 30846875)
Mol Biol Rep. 2020 Dec;47(12):9779-9789. (PMID: 33165817)
J Biomed Sci. 2018 Feb 7;25(1):11. (PMID: 29415742)
Physiol Rev. 2012 Apr;92(2):689-737. (PMID: 22535895)
Zhongguo Zhong Yao Za Zhi. 2020 Oct;45(19):4686-4691. (PMID: 33164433)
Circ Res. 2019 Jan 18;124(2):315-327. (PMID: 30653442)
Int Rev Cell Mol Biol. 2018;335:41-84. (PMID: 29305014)
Mol Cell. 2014 Oct 23;56(2):219-231. (PMID: 25263595)
J Cell Physiol. 2012 Nov;227(11):3575-84. (PMID: 22278285)
Signal Transduct Target Ther. 2017;2:. (PMID: 29158945)
PLoS One. 2014 Oct 31;9(10):e111536. (PMID: 25360664)
J Inflamm Res. 2018 Oct 30;11:407-419. (PMID: 30464573)
Angiology. 2010 May;61(4):357-64. (PMID: 20304866)
Biomolecules. 2018 Aug 23;8(3):. (PMID: 30142970)

0 (Flavonoids)
347Q89U4M5 (baicalin)
EC 3.4.21.5 (Thrombin)

Date Created: 20220131 Date Completed: 20220408 Latest Revision: 20220408

20260130

PMC8799346

10.1155/2022/5799308

35097121